Business Context and Reporting Period
This Form 8-K Current Report was filed by Actinium Pharmaceuticals, Inc. on April 18, 2019. The filing discloses the entry into a material definitive agreement regarding a public offering of common stock and warrants.
Key Financial Metrics and Transaction Details
- Offering Size: 42,860,000 shares of Common Stock and warrants to purchase 42,860,000 shares.
- Offering Price: $0.385 per share and related warrant.
- Underwriting Price: $0.358 per share and related warrant.
- Gross Proceeds: Approximately $16.5 million.
- Net Proceeds: Approximately $15.1 million (after underwriting discounts and offering expenses).
- Warrant Terms: Exercise price of $0.50 per share; exercisable for five years from issuance.
- Warrant Redemption: Company may redeem warrants for $0.001 if Common Stock closes above $1.50 for ten consecutive days.
Material Changes and Transaction Status
The primary material change is the execution of an underwriting agreement with William Blair & Company, L.L.C. The offering is expected to close on April 23, 2019, subject to customary closing conditions. This transaction represents a significant capital raise for the Company.
Guidance, Outlook, and Restrictions
- Lock-Up Period: The Company, its directors, and officers have agreed not to sell or dispose of any securities held by them for 90 days following the date of the final prospectus supplement, without written consent from the Underwriters.
- Regulation FD: Press releases announcing the intent and pricing of the offering were issued on April 17 and April 18, 2019, respectively.
- Financial Outlook: The filing does not provide specific operational guidance or revenue forecasts beyond the expected proceeds from this offering.
Investor Verification Checklist
- Verify the closing of the offering on or around April 23, 2019.
- Confirm the actual net proceeds received after finalizing all offering expenses.
- Monitor the trading price of the Common Stock relative to the $1.50 threshold for potential warrant redemption.
- Review the full Underwriting Agreement (Exhibit 1.1) and Form of Warrant (Exhibit 4.1) for specific covenants and adjustment mechanisms.
- Check for any subsequent filings regarding the use of proceeds or changes in the Company's capital structure.